An observational study in Urothelial Carcinoma Bladder, sponsored by Zeinab Yahia Zaki. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.
Sponsored by Zeinab Yahia Zaki · Observational
Bladder cancer(BC) is the 10th most common cancer globally, with a higher incidence in males than females, being the 6th most common cancer in men with high mortality, causing a societal burden worldwide.
Known risk factors include age, gender, cigarettes, genetic factors, and other environmental influences .
BC can be classified into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC) . MIBC exhibits a more aggressive nature, correlates with a higher level of T-stage, and has more significant genetic heterogeneity .
Despite comprehensive treatment regimens comprising neoadjuvant chemotherapy, radical cystectomy (RC) and adjuvant immunotherapies, a significant proportion of MIBC patients continue to progress to more advanced stages with limited clinical indicators.
Unfortunately, the mechanisms underlying BC initiation, proliferation, and progression remain largely unknown.
The occurrence of genetic alterations is believed to be closely linked to BC tumorigenesis. Therefore, investigating the genetic alterations might offer opportunities to further understand biological changes in BC .
A key mechanism underlying tumor progression and metastasis is the epithelial-mesenchymal transition (EMT), which is associated with increased invasiveness, chemoresistance, and immune evasion.
EMT is characterized by the downregulation of epithelial markers such as E-cadherin (CDH1) and the upregulation of mesenchymal markers like N-cadherin (CDH2), vimentin, Snail, and ZEB proteins .
Emerging evidence suggests that junctional adhesion molecule 3 (JAM3) plays a role in EMT and cancer progression, with documented involvement in gastric cancer.
However, its significance in MIBC remains poorly understood. Investigating JAM3 expression in MIBC may provide novel prognostic insights and help refine patient stratification for NAC and immunotherapy.
Aim:
This study aims to analyze JAM3 expression in transurethral biopsies from MIUC patients and correlate it with:
This study will provide a better understanding of JAM3's role in EMT and MIUC progression, offering potential biomarker-driven insights for treatment stratification.
If JAM3 is validated as a prognostic factor, it could guide personalized therapeutic approaches and optimizing NAC outcomes.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 40 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.
Browse Carcinoma studies →This is the only study on the registry with Zeinab Yahia Zaki as lead sponsor.
Counted across the registry records on this site, refreshed daily.
:Patients diagnosed with muscle invasive urothelial carcinoma( MIUC) and eligible for neoadjuvant chemotherapy( NAC)
Exclusion criteria
* Data record of patient will be reviewed for the following: * Clinical features: * Age * Performance status * Risk factors(smoking,stones or bilharziasis) * Comorbidities * Family history * Pathological features: * Histological subtype * Grade * Muscle invasion * Carcinoma in situ * Immunohistochemistry(IHC): JAM3 expression by IHC * TNM staging * Number of chemotherapy cycles received * Radical surgery or * CCRT and type of concurrent * Post treatment histological response * . Follow-Up and Survival Analysis: * During treatment: Monitoring for adverse events of chemotherapy and clinical response. * After treatment: Imaging and clinical examination every 3 months for 2 years. * Correlation of JAM3 expression with progression-free survival (PFS) and overall survival (OS)..
The response to neoadjuvant chemotherapy in muscle invasive bladder cancer in relation to JAM3 expression
Time frame: from enrollment to the end of treatment at 5 months
No study locations are listed for this record.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.